Showing 5551-5560 of 9878 results for "".
- Exploring the Link Between Sex Hormones and Melanoma Riskhttps://practicaldermatology.com/news/exploring-the-link-between-sex-hormones-and-melanoma-risk/2462016/Researchers out of the University of Tennessee Health Science Center are beginning a study to determine whether sex hormones affect the risk of melanoma The team received a $423,500 grant from the National Institute of Environmental Health Sciences, part of the National Institutes of He
- Severe Psoriasis Increases Risk for Heart Diseasehttps://practicaldermatology.com/news/severe-psoriasis-increases-risk-for-heart-disease/2462013/Researchers have found further evidence that patients with severe psoriasis are at higher risk for cardiovascular disease. In this study, a total of 503 patients with psoriasis, and without clinical cardiovascular disease, underwent transthoracic Doppler echocardiography to evaluate cor
- Study: AD Ups Risk for IBDhttps://practicaldermatology.com/news/study-ad-ups-risk-for-ibd/2462009/Adults with atopic dermatitis (AD) have a 34% increased risk of developing new-onset inflammatory bowel disease (IBD) compared with individuals who do not have the skin condition, and children have a 44% increased risk, according to a new study from the P
- Arcutis Submits NDA for Roflumilast Cream 0.15% for AD Treatmenthttps://practicaldermatology.com/news/arcutis-submits-nda-for-roflumilast-cream-015-for-ad-treatment/2462001/Arcutis Biotherapeutics, Inc. submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older. Roflumilast cream is
- One to Watch: Nektar Therapeutics' Rezpegaldesleukin Shows Promise in Phase 1b AD Studyhttps://practicaldermatology.com/news/one-to-watch-nektar-therapeutics-rezpegaldesleukin-shows-promise-in-phase-1b-ad-study/2462000/Nektar Therapeutics’ rezpegaldesleukin met several clinical efficacy endpoints with statistically significance, including Body Surface Area (BSA), Dermatology Life (DLQI), and Patient-Oriented Eczema Measure (POEM) in addition to reported efficacy for Eczema Area and Severity
- Innovation in Action: A Newly Developed Anti-bacterial Silver Gel May Best Other Silver-based Drugshttps://practicaldermatology.com/news/innovation-in-action-a-newly-developed-anti-bacterial-silver-gel-may-best-other-silver-based-drugs/2461999/A new anti-bacterial gel based on silver and sulfur-containing amino acids may be one hundred times more effective than other silver-based antibacterials, according to research in the Journal of Material
- ‘SUNucate’ Laws Do Increase Interest in Sun Protection, Youth Sunscreen Usehttps://practicaldermatology.com/news/sunucate-laws-do-increase-interest-in-sun-protection-youth-sunscreen-use/2461998/States that enacted SUNUCATE laws permitting children to carry and apply sunscreen at school experienced an increased interest in sun protection and a higher rate of sunscreen use among adolescents, according to new research by a University of Massachusetts Amherst resource economist.
- New Surgical Technique Offers Hope to Folliculitis Decalvans Patientshttps://practicaldermatology.com/news/experimental-surgical-technique-offers-hope-to-folliculitis-decalvans-patients/2461997/The lack of long-term solutions in the challenging treatment of folliculitis decalvans (FD) led Sanusi Umar MD, and colleagues from Dr. U Hair and Skin Clinic to develop and patent a novel device that holds potential for sustained FD remission.
- Cetaphil Takes on Aging Skin with New Skincare Linehttps://practicaldermatology.com/news/cetaphil-takes-on-aging-skin-with-new-skincare-line/2461995/Galderma is rolling out Cetaphil Healthy Renew, its first-ever healthy aging skincare line. "Aging skin is a particular point of frustration for my sensitive skin patients due to increased risks of irritation and an already compromised skin barrier,” says Cetaphil partn
- Hillstream Enters Into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritishttps://practicaldermatology.com/news/hillstream-enters-into-an-exclusive-option-agreement-to-acquire-a-clinical-stage-asset-for-chronic-pruritis/2461994/Hillstream BioPharma, Inc. is set to acquire AV104 for chronic pruritis. AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis. The Company intends to first seek approval in an orphan disease for the treatment of mode